2d
Barchart on MSNWall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?Moderna (MRNA) has been a classic example of how one successful product can propel a biotech stock to new heights in a matter ...
Viking Global Investors' billionaire chief kicked Tesla to the curb in the December-ended quarter in favor of an ...
Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...
We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...
Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.
Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...
In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...
Flu cases are surging, especially among children, forcing a growing number of schools across the country to close. Elevated cases of COVID, RSV and norovirus are also overwhelming the health care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results